Myriad Genetics (MYGN -7.1%) slumps and is now off ~22% since intraday highs hit Thursday after...


Myriad Genetics (MYGN -7.1%) slumps and is now off ~22% since intraday highs hit Thursday after the Supreme Court's ruling on gene patents. Investors' fears that methods outside of MYGN's cDNA synthetics can be used to analyze genes were seemingly confirmed when Quest Diagnostics' (DGX +0.7%) director of media relations said the company plans "to validate and offer a BRCA1 and BRCA2 test service to physicians and patients later this year" (more). "The focus now shifts to the competitive dynamic," Jefferies says, reiterating a Hold rating. Meanwhile, BofA and RBC cut the shares to Neutral and Sector Perform respectively. (previous)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs